Last 22 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 206.20 | 141.67 | 179.99 | 154.00 | 181.47 | 71.54 | 44.78 | 39.66 | 554.41 | — | 309.33 | — | — | — | — | — | — | — | — | — | — |
| — | +98.0% | +301.9% | +288.3% | -67.3% | — | -85.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.72 | 16.43 | 8.04 | 4.27 | 5.49 | 5.24 | 2.44 | 2.26 | 2.45 | 3.12 | 3.00 | 6.48 | 4.52 | 5.52 | 3.93 | 5.71 | — | — | — | — | — |
| — | +213.3% | +229.9% | +88.9% | +124.7% | +68.2% | -18.8% | -65.1% | -45.9% | -43.5% | -23.7% | +13.5% | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | 5.99 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -58.1% | 100.0% | -116.8% | 100.0% | -3491.0% | -67.2% | 100.0% | 100.0% | 100.0% | — | -122.5% | — | — | — | — | — | — | — | — | — | — |
| — | +248.9% | -216.8% | 0.0% | -3591.0% | — | +181.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -4498.1% | -3750.9% | -5917.5% | -5800.5% | -4406.0% | -4787.2% | -3603.3% | -2025.7% | -25948.3% | — | -8179.5% | — | — | — | — | — | — | — | — | — | — |
| — | +21.6% | -64.2% | -186.3% | +83.0% | — | +55.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -4342.4% | -3649.0% | -5738.6% | -5498.7% | -4129.1% | -4716.7% | -3568.8% | -1936.6% | -25128.2% | — | -7743.0% | — | — | — | — | — | — | — | — | — | — |
| — | +22.6% | -60.8% | -183.9% | +83.6% | — | +53.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -146.8% | -72.3% | -49.7% | -32.6% | -45.4% | -62.7% | -39.9% | -24.7% | -27.2% | -25.1% | -24.3% | -40.1% | -23.4% | -16.3% | -13.2% | -16.1% | -19.1% | -13.7% | -10.2% | -23.3% | -5.4% |
| — | -15.3% | -24.6% | -32.1% | -67.0% | -149.5% | -64.3% | +38.5% | -16.4% | -53.8% | -83.4% | -149.9% | -22.2% | -19.6% | -30.1% | +30.9% | -251.2% | — | -32.8% | — | — | |
| ROA | -62.8% | -15.5% | -15.4% | -12.7% | -15.2% | -17.3% | -16.6% | -13.4% | -17.7% | -19.4% | -18.1% | -30.3% | -19.5% | -14.2% | -11.6% | -13.6% | -15.4% | -11.9% | -8.7% | -20.4% | -5.2% |
| — | +10.6% | +7.1% | +5.6% | +14.1% | +10.6% | +8.4% | +55.8% | +9.1% | -36.6% | -55.7% | -122.1% | -26.4% | -18.9% | -33.3% | +33.1% | -196.3% | — | -86.4% | — | — | |
| ROIC | -168.3% | -28.0% | -25.2% | -19.0% | -24.1% | -30.4% | -53.2% | -53.4% | -27.5% | -22.2% | -24.3% | -37.5% | -24.7% | -21.5% | -18.3% | -18.5% | -15.9% | -18.3% | -21.7% | -51.5% | -7.1% |
| — | +8.1% | +52.6% | +64.3% | +12.4% | -37.1% | -119.1% | -42.4% | -11.3% | -3.5% | -33.0% | -102.7% | -56.0% | -17.5% | +16.0% | +64.1% | -124.0% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.96 | 2.83 | 1.49 | 0.96 | 0.73 | 1.97 | 1.13 | 0.27 | 0.22 | 0.21 | 0.18 | 0.10 | 0.09 | 0.11 | 0.09 | 0.09 | 0.18 | 0.17 | 0.04 | 0.04 | 0.03 |
| — | +43.6% | +31.8% | +261.6% | +235.4% | +830.1% | +530.7% | +160.0% | +147.7% | +99.6% | +92.9% | +12.7% | -51.7% | -38.7% | +163.2% | +109.2% | +463.2% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.84 | 3.05 | 3.80 | 4.84 | 6.61 | 3.56 | 4.78 | 5.58 | 6.50 | 8.23 | 8.91 | 2.53 | 4.69 | 7.61 | 10.62 | 11.10 | 6.70 | 7.62 | 16.44 | 4.67 | 31.48 |
| — | -14.1% | -20.4% | -13.3% | +1.7% | -56.8% | -46.4% | +120.3% | +38.6% | +8.2% | -16.1% | -77.2% | -30.0% | -0.2% | -35.4% | +137.9% | -78.7% | — | +498.7% | — | — | |
| Quick Ratio | 4.84 | 3.05 | 3.80 | 4.84 | 6.61 | 3.56 | 4.78 | 5.58 | 6.50 | 8.23 | 8.91 | 2.53 | 4.69 | 7.61 | 10.62 | 11.10 | 6.70 | 7.62 | 16.44 | 4.67 | 31.48 |
| — | -14.1% | -20.4% | -13.3% | +1.7% | -56.8% | -46.4% | +120.3% | +38.6% | +8.2% | -16.1% | -77.2% | -30.0% | -0.2% | -35.4% | +137.9% | -78.7% | — | +498.7% | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PRME stock.
Prime Medicine, Inc.'s current P/E is -4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Prime Medicine, Inc.'s current operating margin is -4498.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Prime Medicine, Inc.'s business trajectory between earnings reports.